肺栓塞英文版分析.pptVIP

Chai Lin Pulmonary embolism(PE): Embolus from circulation or right heart shedding and blocking obstruction of the pulmonary artery and its branches cause pulmonary circulation obstacle. The most common pulmonary embolus for thrombosis, blood clots caused by pulmonary embolism or pulmonary embolism. Superior vena cava Patients with sudden unexplained collapse, pale, cold sweat, difficulty breathing, chest pain, cough, and cerebral hypoxia symptoms such as extreme anxiety, fatigue, nausea, convulsions and coma. The clinical symptoms and signs of PE are not obvious, and it is likely to be missed. The clinical manifestations of patients with PE, must immediately further objective examination. Pleuritic chest pain Pain in the chest Hemoptysis Vertigo half or both lower extremities pai Unilateral limb swelling Inferior vena cava Pulmonary artery Embolus Lower extremity venous color Doppler ultrasound Lung ventilation / perfusion scan Pulmonary artery angiography Anticoagulation The aim of anticoagulation therapy in patients with acute PE is to prevent early death and recurrence or fatal VTE (venous thromboembolism). Standard anticoagulant therapy for at least 3 months. During this period, the acute phase of treatment was used in the first 5-10 days of parenteral anticoagulation (common heparin, low molecular weight heparin). Then the vitamin K antagonist was used to maintain the treatment, and the initial treatment of the drug should be overlapped with heparin for injection. The goal of anticoagulant therapy in patients with pulmonary embolism is to prevent the recurrence of venous thromboembolism. In most cases, the use of vitamin K antagonists, while in the patients with VTE combined tumor, the application of low molecular weight heparin. Compared with the single application of common heparin, acute PE thrombolysis can recover the pulmonary blood flow faster. Early release of pulmonary vascular occlusion can make the pulmonary arterial pressure and resistance decrea